{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:58:01Z","timestamp":1788141481137,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proteinuria is a strong predictor of graft failure in kidney transplant recipients (KTRs). While non-steroidal mineralocorticoid receptor antagonists (NS-MRAs), particularly finerenone, have demonstrated renoprotective benefits in chronic kidney disease, KTRs were excluded from pivotal trials. Evidence on finerenone\u2019s safety and antiproteinuric effects in this population remains limited. This retrospective observational study evaluated 13 diabetic KTRs with persistent proteinuria despite optimized renin\u2013angiotensin system blockade and sodium\u2013glucose cotransporter 2 inhibitor therapy. Finerenone (10 mg\/day) was added to standard care. Clinical and laboratory parameters, including estimated glomerular filtration rate (eGFR), serum electrolytes, total proteinuria, albuminuria, and their creatinine ratios, were assessed at baseline, 3 months, and 6 months. Safety outcomes focused on hyperkalemia and eGFR. Finerenone was discontinued in one patient due to hyperkalemia. In the remaining 12, 24-h proteinuria and urinary protein-to-creatinine ratio declined at 3 months and stabilized by 6 months. Conversely, no statistically significant changes were observed in albuminuria or the albumin-to-creatinine ratio. No clinically relevant changes occurred in eGFR, blood pressure, body weight, or serum electrolytes. This is the first study assessing finerenone in diabetic KTRs. Finerenone was well tolerated, was associated with an early reduction in proteinuria, and showed no adverse effects on graft function. These findings provide novel insights into the safety and potential role of finerenone in kidney transplant recipients.<\/jats:p>","DOI":"10.3390\/ijms27114832","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:36:56Z","timestamp":1779892616000},"page":"4832","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-237X","authenticated-orcid":false,"given":"Carmine","family":"Secondulfo","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-1049","authenticated-orcid":false,"given":"Nicoletta","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9453-7258","authenticated-orcid":false,"given":"Gianmarco","family":"Minelli","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Apicella","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Iacuzzo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Crescenzo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maristella","family":"Minco","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sannino","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Clemente","sequence":"additional","affiliation":[{"name":"Unit of Diabetology and Nutrition, University Hospital of Salerno \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-3504","authenticated-orcid":false,"given":"Massimo","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Bilancio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, Regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/TP.0000000000003137","article-title":"Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-Term Kidney Transplant Graft Survival\u2014Making Progress When Most Needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Harding, J.L., Pavkov, M., Wang, Z., Benoit, S., Burrows, N.R., Imperatore, G., Albright, A.L., and Patzer, R. (2021). Long-Term Mortality among Kidney Transplant Recipients with and without Diabetes: A Nationwide Cohort Study in the USA. BMJ Open Diabetes Res. Care, 9.","DOI":"10.1136\/bmjdrc-2020-001962"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","article-title":"The Promise of Tubule Biomarkers in Kidney Disease: A Review","volume":"78","author":"Ix","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2215\/CJN.01310211","article-title":"Posttransplantation Proteinuria: An Approach to Diagnosis and Management","volume":"6","author":"Shamseddin","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1432-2277.2012.01500.x","article-title":"Proteinuria after Kidney Transplantation","volume":"25","author":"Ponticelli","year":"2012","journal-title":"Transpl. Int."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bilancio, G., Hamzeh, S., Vecchione, N., Russo, D., Iacuzzo, C., Apicella, L., Di Pietro, R.A., Vitale, P., Amicone, M., and Pisani, A. (2025). Dapagliflozin\u2019s Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061303"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in Posttransplantation Diabetes Mellitus: A Prospective, Interventional Pilot Study on Glucose Metabolism, Fluid Volume, and Patient Safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.34067\/KID.0000732021","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MNH.0000000000000948","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Cardiorenal Outcomes in Kidney Transplantation","volume":"33","author":"Mahalwar","year":"2024","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ekir.2024.11.033","article-title":"Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients","volume":"10","author":"Maigret","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Secondulfo, C., Vecchione, N., Russo, D., Hamzeh, S., Iacuzzo, C., Apicella, L., Di Pietro, R.A., Pisani, A., Amicone, M., and Cirillo, M. (2025). Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26072904"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11255-024-04256-6","article-title":"Mineralocorticoid Receptor Blockage in Kidney Transplantation: Too Much of a Good Thing or Not?","volume":"57","author":"Afsar","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1111\/bph.15782","article-title":"The Role of the Mineralocorticoid Receptor in Immune Cells in Cardiovascular Disease","volume":"179","author":"Bode","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists","volume":"54","author":"Mende","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-022-01166-9","article-title":"Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage","volume":"24","author":"Upadhya","year":"2022","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation Between Kidney Function, Proteinuria, and Adverse Outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kahvecioglu, S., Celik, H., Yalcinkaya, A.S., Ayar, Y., Aktas, N., and Akarsu, O. (2025). Efficacy and Safety of Finerenone in Kidney Transplant Patients. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238296"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.0000000000000439","article-title":"Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN Trial): A Randomized Placebo-Controlled Clinical Trial","volume":"19","author":"Mortensen","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"F519","DOI":"10.1152\/ajprenal.00606.2018","article-title":"Spironolactone Reduces Oxidative Stress in Living Donor Kidney Transplantation: A Randomized Controlled Trial","volume":"317","author":"Marino","year":"2019","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.transproceed.2017.01.075","article-title":"Spironolactone in Post-Transplant Proteinuria: A Safe Alternative Therapy","volume":"49","author":"Guida","year":"2017","journal-title":"Transplant. Proc."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Baskin, E., Siddiqui, M.A., G\u00fcllero\u011flu, K., \u00d6zdemir, B.H., Y\u0131lmaz, A.\u00c7., \u00c7olak, M.Y., Akdur, A., Soy, E.A., Moray, G., and Haberal, M. (2023). Long-Term Effect of Eplerenone Treatment in Children with Chronic Allograft Nephropathy. Pediatr. Transplant., 27.","DOI":"10.1111\/petr.14557"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.transproceed.2017.09.005","article-title":"Early Prediction of Cardiovascular Disease in Kidney Transplant Recipients","volume":"49","author":"Bilancio","year":"2017","journal-title":"Transplant. Proc."},{"key":"ref_29","unstructured":"(2026, January 30). Agenzia Italiana del Farmaco Riclassificazione Del Medicinale per Uso Umano \u00abKerendia\u00bb, Ai Sensi Dell\u2019articolo 8, Comma 10, Della Legge 24 Dicembre 1993, n. 537. (Determina n. 31\/2024). (24A02808) (GU Serie Generale n.132 Del 07-06-2024; 2024). Available online: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2024-06-07&atto.codiceRedazionale=24A02808."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","article-title":"Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program","volume":"52","author":"Myers","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee 2 (2023). Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S20\u2013S42.","DOI":"10.2337\/dc24-S002"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients: A Summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int."},{"key":"ref_34","unstructured":"(2026, January 30). University of North Carolina, Chapel Hill. The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study, Available online: https:\/\/clinicaltrials.gov\/."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4832\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:30:23Z","timestamp":1780399823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27114832"],"URL":"https:\/\/doi.org\/10.3390\/ijms27114832","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}